PRODUCT | CATHEGORY | STATUS |
---|---|---|
ALECTINIB | Lung cancer | Early development |
ATROPINE | Eye surgery | Commercial – DMF |
AXITINIB | Breast cancer | Early development |
CLASCOTERONE | Acne | Ready for validation |
CRIZOTINIB | Non-small cell lung cancer | Early development |
CYSTEAMINE BITARTRATE | Cystinosis | Commercial – DMF |
CYSTEAMINE HCL | Cystinosis | Ready for validation |
DIMETHYL FUMARATE | Multiple sclerosis | Ready for validation |
IGURATIMOD | Rheumatoid arthritis | Ready for validation |
NILOTINIB | Leukemia | Ready for validation |
RUCAPARIB | Ovarian cancer | Under evaluation |
RUXOLITINIB | Myelofibrosis | Ready for validation |
TEGOPRAZAN | Gastrointestinal diseases | Under evaluation |
VILANTEROL | Obstructive Pulmonary Disease | Ready for validation |
VORTIOXETINE | Major Depressive Disorder | Ready for validation |
Development, manufacturing, marketing of the above products is performed in countries where such activities are not in conflict with the existing patents. |